ReviewFrontiers in neuroscience2019
Immune Mediated Degeneration and Possible Protection in Glaucoma.
Review in Frontiers in neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04676126 (Augmented Macular Pigment Supplement and Pericentral Visual Function), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Augmented Macular Pigment Supplement and Pericentral Visual Function: a Randomized Controlled Trial
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- CTCF-FXN regulatory axis plays critical roles in clinical assessments and disease progression of primary open-angle glaucoma.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Potential Functions and Causal Associations of GNLY in Primary Open-Angle Glaucoma: Integration of Blood-Derived Proteome, Transcriptome, and Experimental Verification.Journal of inflammation research · 2025Article
- Role of T cell-induced autoimmune response in the pathogenesis of glaucoma.International ophthalmology · 2024Review
- Protection against Oxidative Stress by Coenzyme Q10 in a Porcine Retinal Degeneration Model.Journal of personalized medicine · 2024Article
- Immune Analysis Using Vitreous Optical Coherence Tomography Imaging in Rats with Steroid-Induced Glaucoma.Biomedicines · 2024Article
- Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models.Biomolecules · 2022Article
- Analysis of Parainflammation in Chronic Glaucoma Using Vitreous-OCT Imaging.Biomedicines · 2021Article
- Effects of a New Combination of Natural Extracts on Glaucoma-Related Retinal Degeneration.Foods (Basel, Switzerland) · 2021Article
- Article
- Axonopathy precedes cell death in ocular damage mediated by blast exposure.Scientific reports · 2021Article
- Glial Cells in Glaucoma: Friends, Foes, and Potential Therapeutic Targets.Frontiers in neurology · 2021Review
- Inhibitory and Agonistic Autoantibodies Directed Against the βFrontiers in neuroscience · 2021Article
- Evaluation of the Effectiveness of a Chronic Ocular Hypertension Mouse Model Induced by Intracameral Injection of Cross-Linking Hydrogel.Frontiers in medicine · 2021Article
- Oxidative Stress and Vascular Dysfunction in the Retina: Therapeutic Strategies.Antioxidants (Basel, Switzerland) · 2020Review
- Association between ActiveMicroorganisms · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The underlying pathomechanisms for glaucoma, one of the most common causes of blindness worldwide, are still not identified. In addition to increased intraocular pressure (IOP), oxidative stress, excitotoxicity, and immunological processes seem to play a role. Several pharmacological or molecular/genetic methods are currently investigated as treatment options for this disease. Altered autoantibody levels were detected in serum, aqueous humor, and tissue sections of glaucoma patients. To further analyze the role of the immune system, an IOP-independent, experimental autoimmune glaucoma (EAG) animal model was developed. In this model, immunization with ocular antigens leads to antibody depositions, misdirected T-cells, retinal ganglion cell death and degeneration of the optic nerve, similar to glaucomatous degeneration in patients. Moreover, an activation of the complement system and microglia alterations were identified in the EAG as well as in ocular hypertension models. The inhibition of these factors can alleviate degeneration in glaucoma models with and without high IOP. Currently, several neuroprotective approaches are tested in distinct models. It is necessary to have systems that cover underlying pathomechanisms, but also allow for the screening of new drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.